Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification [clinicaltrials:NCT00496041]

Bio2RDF uri

Belgian Prospective Multicentre Registry on the Performance of the Smart Stent in the Superficial Femoral Artery According to the New Tasc II-classification [clinicaltrials:NCT00496041]

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

http://bio2rdf.org/clinicaltrials:NCT00496041

Bio2RDF identifier

NCT00496041

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT00496041

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT00496041

anticipated enrollment [clinicaltrials_vocabulary:anticipated-enrollment]

200

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT00496041 arm group b68a8617da39dae5e16f67ca9dc6119e [clinicaltrials_resource:NCT00496041/arm-group/b68a8617da39dae5e16f67ca9dc6119e]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:2bfd02cc7a6d0fdea45d79b9df9e55de

brief summary [clinicaltrials_vocabulary:brief-summary]

This is a Belgian prosp ...... e new tasc II-classification.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

Belgian Prospective Multicentr ...... the New Tasc II-classification

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:5365a589e427c8a101389e0082d319a9]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:29342436813fb1b48532fb0109ae766d]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:2a3aef36bd6087bca32f94d581d0f8c4]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:8a7f756a207c5bb61eff5ca3811c2d17]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:a9c4cb9e16f44b5fce24ba8124c0610d]

Patency as defined by absence of occlusion or >50% restenosis rate at the level the treated lesion as determined by duplex control. 1 year [clinicaltrials_resource:cdb6b1ce145d56907dff166d6537ee8d]

completion date [clinicaltrials_vocabulary:completion-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT00496041 [clinicaltrials_resource:dbc76e8f638bf5e8b6caf81b40c7734d]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2007-07-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Registry [clinicaltrials_resource:f04598b1046315b0d26b94d0fdf2ced7]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Stenosis (> 75%) or occlusion of the superficial femoral artery

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2014-12-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

University Hospital, Ghent [clinicaltrials_resource:1152a90af2c2f424085599069a2c92f5]

link [clinicaltrials_vocabulary:link]

University Hospital Ghent [clinicaltrials_resource:9a7ebe0c0da1b1598faa965a85e2fb92]

location [clinicaltrials_vocabulary:location]

University Hospital Ghent [clinicaltrials_resource:b16404d6f3fd17ff6c702d345c7b0edf]

nct id [clinicaltrials_vocabulary:nct-id]

NCT00496041

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

Belgian Prospective Multicentr ...... the New Tasc II-classification

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

2007/208

http://www.w3.org/2001/XMLSchema#string

overall contact [clinicaltrials_vocabulary:overall-contact]

Frank Vermassen, MD, PhD [clinicaltrials_resource:c8eabaa0f7b7b80b19f2e708776181dd]

overall official [clinicaltrials_vocabulary:overall-official]

Frank Vermassen, MD, PhD [clinicaltrials_resource:48d236e7a0b90d0c2009fc1733c2bdda]

overall status [clinicaltrials_vocabulary:overall-status]

Recruiting [clinicaltrials_resource:5231dee7156b84b0d1854de1a18dd169]

oversight [clinicaltrials_vocabulary:oversight]

Belgium: Institutional Review Board [clinicaltrials_resource:842f761175444b2e55ff50f5a7be6779]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:dbd41868ee618d3e64daa1adf8c3a8a0]

source [clinicaltrials_vocabulary:source]

University Hospital, Ghent [clinicaltrials_resource:1152a90af2c2f424085599069a2c92f5]

start date [clinicaltrials_vocabulary:start-date]

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT00496041 study design [clinicaltrials_resource:a55da13e1c541896edc86a389b9a4084]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT00496041

verification date [clinicaltrials_vocabulary:verification-date]

2014-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

identifier

clinicaltrials:NCT00496041

http://www.w3.org/2001/XMLSchema#string

title

Belgian Prospective Multicentr ...... the New Tasc II-classification

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]

label

Belgian Prospective Multicentr ...... n [clinicaltrials:NCT00496041]

@en